Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Priscilla R. Prestes is active.

Publication


Featured researches published by Priscilla R. Prestes.


Frontiers in Genetics | 2016

Muscle-Enriched MicroRNAs Isolated from Whole Blood Are Regulated by Exercise and Are Potential Biomarkers of Cardiorespiratory Fitness

Joshua Denham; Priscilla R. Prestes

MicroRNAs (miRNAs) are small non-coding RNA molecules that regulate gene expression post-transcriptionally. Evidence indicating miRNAs influence exercise-induced health and performance adaptations is mounting. Circulating miRNAs are responsible for intercellular communication and could serve as biomarkers for disease and exercise-related traits. Such biomarkers would contribute to exercise screening, monitoring, and the development of personalized exercise prescription. Accordingly, we investigated the impact of long-term strenuous aerobic exercise training and a single bout of maximal aerobic exercise on five muscle-enriched miRNAs implicated in exercise adaptations (miR-1, miR-133a, miR-181a, miR-486, and miR-494). We also determined linear correlations between miRNAs, resting heart rate, and maximum oxygen uptake (O2 max). We used TaqMan assay quantitative polymerase chain reaction to analyze the abundance of miR-1, miR-133a, miR-181a, miR-486, and miR-494 in resting whole blood of 67 endurance athletes and 61 healthy controls. Relative to controls, endurance athletes exhibited increased miR-1, miR-486, and miR-494 content (1.26- to 1.58-fold change, all p < 0.05). miR-1, miR-133a, and miR-486 were decreased immediately after maximal aerobic exercise (0.64- to 0.76-fold change, all p < 0.01) performed by 19 healthy, young men (20.7 ± 2.4 years). Finally, we observed positive correlations between miRNA abundance and O2 max (miR-1 and miR-486) and an inverse correlation between miR-486 and resting heart rate. Therefore, muscle-enriched miRNAs isolated from whole blood are regulated by acute and long-term aerobic exercise training and could serve as biomarkers of cardiorespiratory fitness.


Journal of Applied Physiology | 2016

Increased expression of telomere-regulating genes in endurance athletes with long leukocyte telomeres

Joshua Denham; Brendan J. O'Brien; Priscilla R. Prestes; Nicholas J. Brown; Fadi J. Charchar

Leukocyte telomeres shorten with age, and excessive shortening is associated with age-related cardiometabolic diseases. Exercise training may prevent disease through telomere length maintenance although the optimal amount of exercise that attenuates telomere attrition is unknown. Furthermore, the underlying molecular mechanisms responsible for the enhanced telomere maintenance observed in endurance athletes is poorly understood. We quantified the leukocyte telomere length and analyzed the expression of telomere-regulating genes in endurance athletes and healthy controls (both n = 61), using quantitative PCR. We found endurance athletes have significantly longer (7.1%, 208-416 nt) leukocyte telomeres and upregulated TERT (2.0-fold) and TPP1 (1.3-fold) mRNA expression compared with controls in age-adjusted analysis. The telomere length and telomere-regulating gene expression differences were no longer statistically significant after adjustment for resting heart rate and relative V̇O(2 max) (all P > 0.05). Resting heart rate emerged as an independent predictor of leukocyte telomere length and TERT and TPP1 mRNA expression in stepwise regression models. To gauge whether volume of exercise was associated with leukocyte telomere length, we divided subjects into running and cycling tertiles (distance covered per week) and found individuals in the middle and highest tertiles had longer telomeres than individuals in the lowest tertile. These data emphasize the importance of cardiorespiratory fitness and exercise training in the prevention of biological aging. They also support the concept that moderate amounts of exercise training protects against biological aging, while higher amounts may not elicit additional benefits.


BMC Medical Genomics | 2014

Measurement of absolute copy number variation reveals association with essential hypertension

Francine Z. Marques; Priscilla R. Prestes; Leonardo Pinheiro; Katrina J. Scurrah; Kerry R. Emslie; Maciej Tomaszewski; Stephen B. Harrap; Fadi J. Charchar

BackgroundThe role of copy number variation (CNV) has been poorly explored in essential hypertension in part due to technical difficulties in accurately assessing absolute numbers of DNA copies. Droplet digital PCR (ddPCR) provides a powerful new approach to CNV quantitation. The aim of our study was to investigate whether CNVs located in regions previously associated with blood pressure (BP) variation in genome-wide association studies (GWAS) were associated with essential hypertension by the use of ddPCR.MethodsUsing a “power of extreme” approach, we quantified nucleic acids using ddPCR in white subjects from the Victorian Family Heart Study with extremely high (n = 96) and low (n = 92) SBP, providing power equivalent to 1714 subjects selected at random.ResultsA deletion of the CNVs esv27061 and esv2757747 on chromosome 1p13.2 was significantly more prevalent in extreme high BP subjects after adjustment for age, body mass index and sex (12.6% vs. 2.2%; P = 0.013).ConclusionsOur data suggests that CNVs within regions identified in previous GWAS may play a role in human essential hypertension.


Physiological Genomics | 2016

Telomere dynamics during aging in polygenic left ventricular hypertrophy

Francine Z. Marques; Scott A. Booth; Priscilla R. Prestes; Claire L. Curl; Lea M.D. Delbridge; Paul Lewandowski; Stephen B. Harrap; Fadi J. Charchar

Short telomeres are associated with increased risk of cardiovascular disease. Here we studied cardiomyocyte telomere length at key ages during the ontogeny of cardiac hypertrophy and failure in the hypertrophic heart rat (HHR) and compared these with the normal heart rat (NHR) control strain. Key ages corresponded with the pathophysiological sequence beginning with fewer cardiomyocytes (2 days), leading to left ventricular hypertrophy (LVH) (13 wk) and subsequently progression to heart failure (38 wk). We measured telomere length, tissue activity of telomerase, mRNA levels of telomerase reverse transcriptase (Tert) and telomerase RNA component (Terc), and expression of the telomeric regulator microRNA miR-34a. Cardiac telomere length was longer in the HHR compared with the control strain at 2 days and 38 wk, but shorter at 13 wk. Neonatal HHR had higher cardiac telomerase activity and expression of Tert and miR-34a. Telomerase activity was not different at 13 or 38 wk. Tert mRNA and Terc RNA were overexpressed at 38 wk, while miR-34a was overexpressed at 13 wk but downregulated at 38 wk. Circulating leukocytes were strongly correlated with cardiac telomere length in the HHR only. The longer neonatal telomeres in HHR are likely to reflect fewer fetal and early postnatal cardiomyocyte cell divisions and explain the reduced total cardiomyocyte complement that predisposes to later hypertrophy and failure. Although shorter telomeres were a feature of cardiac hypertrophy at 13 wk, they were not present at the progression to heart failure at 38 wk.


Journal of the American Heart Association | 2017

Experimental and Human Evidence for Lipocalin-2 (Neutrophil Gelatinase-Associated Lipocalin [NGAL]) in the Development of Cardiac Hypertrophy and heart failure

Francine Z. Marques; Priscilla R. Prestes; Sean G. Byars; Scott C. Ritchie; Peter Würtz; Sheila K. Patel; Scott A. Booth; Indrajeetsinh Rana; Yosuke Minoda; Stuart P. Berzins; Claire L. Curl; Jimmy D. Bell; Bryan Wai; P. Srivastava; Antti J. Kangas; Pasi Soininen; Saku Ruohonen; Mika Kähönen; Terho Lehtimäki; Emma Raitoharju; Aki S. Havulinna; Markus Perola; Olli T. Raitakari; Veikko Salomaa; Mika Ala-Korpela; Johannes Kettunen; M. McGlynn; Jason Kelly; Mary E. Wlodek; Paul Lewandowski

Background Cardiac hypertrophy increases the risk of developing heart failure and cardiovascular death. The neutrophil inflammatory protein, lipocalin‐2 (LCN2/NGAL), is elevated in certain forms of cardiac hypertrophy and acute heart failure. However, a specific role for LCN2 in predisposition and etiology of hypertrophy and the relevant genetic determinants are unclear. Here, we defined the role of LCN2 in concentric cardiac hypertrophy in terms of pathophysiology, inflammatory expression networks, and genomic determinants. Methods and Results We used 3 experimental models: a polygenic model of cardiac hypertrophy and heart failure, a model of intrauterine growth restriction and Lcn2‐knockout mouse; cultured cardiomyocytes; and 2 human cohorts: 114 type 2 diabetes mellitus patients and 2064 healthy subjects of the YFS (Young Finns Study). In hypertrophic heart rats, cardiac and circulating Lcn2 was significantly overexpressed before, during, and after development of cardiac hypertrophy and heart failure. Lcn2 expression was increased in hypertrophic hearts in a model of intrauterine growth restriction, whereas Lcn2‐knockout mice had smaller hearts. In cultured cardiomyocytes, Lcn2 activated molecular hypertrophic pathways and increased cell size, but reduced proliferation and cell numbers. Increased LCN2 was associated with cardiac hypertrophy and diastolic dysfunction in diabetes mellitus. In the YFS,LCN2 expression was associated with body mass index and cardiac mass and with levels of inflammatory markers. The single‐nucleotide polymorphism, rs13297295, located near LCN2 defined a significant cis‐eQTL for LCN2 expression. Conclusions Direct effects of LCN2 on cardiomyocyte size and number and the consistent associations in experimental and human analyses reveal a central role for LCN2 in the ontogeny of cardiac hypertrophy and heart failure.


F1000Research | 2017

Best practice data life cycle approaches for the life sciences

Philippa C. Griffin; Jyoti Khadake; Kate LeMay; Suzanna E. Lewis; Sandra Orchard; Andrew J. Pask; Bernard J. Pope; Ute Roessner; Keith Russell; Torsten Seemann; Andrew E. Treloar; Sonika Tyagi; Jeffrey H. Christiansen; Saravanan Dayalan; Simon Gladman; Sandra B. Hangartner; Helen L. Hayden; William Ho; Gabriel Keeble-Gagnere; Pasi K. Korhonen; Peter Neish; Priscilla R. Prestes; Mark F. Richardson; Nathan S. Watson-Haigh; Kelly L. Wyres; Neil D. Young; Maria Victoria Schneider

Throughout history, the life sciences have been revolutionised by technological advances; in our era this is manifested by advances in instrumentation for data generation, and consequently researchers now routinely handle large amounts of heterogeneous data in digital formats. The simultaneous transitions towards biology as a data science and towards a ‘life cycle’ view of research data pose new challenges. Researchers face a bewildering landscape of data management requirements, recommendations and regulations, without necessarily being able to access data management training or possessing a clear understanding of practical approaches that can assist in data management in their particular research domain. Here we provide an overview of best practice data life cycle approaches for researchers in the life sciences/bioinformatics space with a particular focus on ‘omics’ datasets and computer-based data processing and analysis. We discuss the different stages of the data life cycle and provide practical suggestions for useful tools and resources to improve data management practices.


Journal of Hypertension | 2016

YIA 03-04 EPIGENETIC CHANGES AFTER ACUTE TREATMENT WITH ACUTE ANGIOTENSIN CONVERTING ENZYME INHIBITORS (ACEi).

De Vries N; Priscilla R. Prestes; Indrajeetsinh Rana; Stephen B. Harrap; Fadi J. Charchar

Objective: The ‘legacy effect’ of hypertension treatment is where short term treatment with blood pressure (BP) lowering drugs such as angiotensin converting enzyme inhibitors (ACEi) is followed by a persistent reduction in BP, reduced cardiovascular complications and increased lifespan. However, the involvement of epigenetics mechanisms remains unclear. DNA methylation is the binding of a methyl group to DNA which inhibits gene transcription. The aim of this study is to investigate DNA methylation changes after short term treatment with ACEi. Design and Method: Spontaneously hypertensive rats were treated with the ACEi perindopril for 48 hours at 6 weeks old. Average global DNA methylation was quantified in renal cortices from perindopril (n = 6) and vehicle-treated animals (n = 6) using the 5-mC ELISA Kit (Zymo Research, USA) which features a unique anti-5-methylcytosine monoclonal antibody that is both sensitive and specific for 5-mC. We also measured the expression of epigenetic regulators histone deacetylase 1 (Hdac1), solute carrier family 16 member 3 (monocarboxylate transporter, Mct3) and DNA (cytosine-5-)-methyltransferase 1 (Dnmt1) using quantitative PCR. Results: Global DNA methylation was reduced in the renal cortices of animals treated with ACEi (P < 0.05, Figure 1). Acute treatment with perindopril did not significantly change the renal expression of Hdac1, Dnmt1 and Mct3 (P > 0.05). Conclusions: Acute treatment by ACEi results in a reduction in global DNA methylation indicating that epigenetics may play an important role in the ‘legacy effect’. Further investigation into which specific genes contribute to these changes and if longer course of treatment have a higher impact in the expression of such genes is important.


Physiological Genomics | 2018

Involvement of human monogenic cardiomyopathy genes in experimental polygenic cardiac hypertrophy

Priscilla R. Prestes; Francine Z. Marques; Guillermo López-Campos; Paul Lewandowski; Lea M.D. Delbridge; Fadi J. Charchar; Stephen B. Harrap

Hypertrophic cardiomyopathy thickens heart muscles, reducing functionality and increasing risk of cardiac disease and morbidity. Genetic factors are involved, but their contribution is poorly understood. We used the hypertrophic heart rat (HHR), a unique normotensive polygenic model of cardiac hypertrophy and heart failure, to investigate the role of genes associated with monogenic human cardiomyopathy. We selected 42 genes involved in monogenic human cardiomyopathies to study: 1) DNA variants, by sequencing the whole genome of 13-wk-old HHR and age-matched normal heart rat (NHR), its genetic control strain; 2) mRNA expression, by targeted RNA-sequencing in left ventricles of HHR and NHR at 5 ages (2 days old and 4, 13, 33, and 50 wk old) compared with human idiopathic dilated cardiomyopathy data; and 3) microRNA expression, with rat microRNA microarrays in left ventricles of 2-day-old HHR and age-matched NHR. We also investigated experimentally validated microRNA-mRNA interactions. Whole-genome sequencing revealed unique variants mostly located in noncoding regions of HHR and NHR. We found 29 genes differentially expressed in at least 1 age. Genes encoding desmoglein 2 ( Dsg2) and transthyretin ( Ttr) were significantly differentially expressed at all ages in the HHR, but only Ttr was also differentially expressed in human idiopathic cardiomyopathy. Lastly, only two microRNAs differentially expressed in the HHR were present in our comparison of validated microRNA-mRNA interactions. These two microRNAs interact with five of the genes studied. Our study shows that genes involved in monogenic forms of human cardiomyopathies may also influence polygenic forms of the disease.


Journal of Hypertension | 2016

[PS 01-07] THE EFFECT OF GENES INVOLVED IN MONOGENIC HUMAN CARDIOMYOPATHIES IN A POLYGENIC MODEL OF CARDIAC HYPERTROPHY

Priscilla R. Prestes; Francine Z. Marques; Claire L. Curl; Paul Lewandowski; Lea M.D. Delbridge; Stephen B. Harrap; Fadi J. Charchar

Objective: Cardiac hypertrophy (CH) is the main risk factor for heart disease after age. Genetic factors are known to be involved, but their contribution is still poorly understood. We hypothesise that genes implicated in monogenic human forms of CH might also be involved in the more common polygenic forms of the disease. Our aim was to use the hypertrophic heart rat (HHR), a unique normotensive polygenic model of CH, to investigate mRNA expression of genes previously described to be associated with monogenic forms of dilated and hypertrophic cardiomyopathy in humans. Design and Method: We measured the expression of 37 transcripts with the TruSeq Targeted RNA expression kit using the MiSeq Desktop sequencer (Illumina) in left ventricles of HHR and its sister control strain, the normal heart rat (NHR), at five ages (2 days old, 4-, 13-, 33- and 50 weeks old). Results: We found only one gene (Ttr) differentially expressed in all age groups (FDR<0.1; P < 0.05). Ttr is involved in cardiac amyloidosis, infiltrating cardiovascular structures, leading to hypertrophy. However, in animals older than 13 weeks old, when CH is established in the HHR, we found four genes upregulated (Actc1, Ankrd1, Cav3 and Fhl2). These genes are involved in a variety of muscle development pathways, growth and contractibility. Interestingly, Ankrd1 (fold change 1.3–2.47) has been described to be upregulated in the failing myocardium of dogs and in the left ventricles of patients with CH. Fhl2 is associated with cardiomyopathy in rats but seems to not be essential in cardiac development in mice. Conclusions: Our results show that genes involved in monogenic forms of human CH may also influence polygenic forms of the disease and deserve further investigation.


Nature Communications | 2018

Molecular insights into genome-wide association studies of chronic kidney disease-defining traits

Xiaoguang Xu; James Eales; Artur Akbarov; Hui Guo; Lorenz Becker; David Talavera; Fehzan Ashraf; Jabran Nawaz; Sanjeev Pramanik; John Bowes; Xiao Jiang; John Dormer; A Antczak; Monika Sszulinska; Ingrid Wise; Priscilla R. Prestes; Maciej Glyda; Paweł Bogdański; Ewa Zukowska-Szczechowska; Carlo Berzuini; Adrian S. Woolf; Nilesh J. Samani; Fadi J. Charchar; Maciej Tomaszewski

Collaboration


Dive into the Priscilla R. Prestes's collaboration.

Top Co-Authors

Avatar

Fadi J. Charchar

Federation University Australia

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Francine Z. Marques

Federation University Australia

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Scott A. Booth

Federation University Australia

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Indrajeetsinh Rana

Federation University Australia

View shared research outputs
Researchain Logo
Decentralizing Knowledge